Abstract | PURPOSE: Human Papillomaviruses (HPV) are epitheliotropic for stratified malpighian epithelia such as those of the cervix. Among them, oncogenic viruses are detectable in 99.7% of cervical cancers. A great priority is to develop a vaccine either against primary infection (preventive vaccine) allowing protection against HPV infection or therapeutic vaccine in order to kill previously infected or transformed keratinocytes. CURRENT KNOWLEDGE AND KEY POINTS: Preventive vaccines against HPV contain virus like particles (VLP) 16 and 18 and induce a high titer of blood anti-VLP antibodies. They were recently tested in humans and have shown true efficiency for the prevention of cervical cancer. The therapeutic vaccines are therefore currently being developed in order to increase anti-HPV natural CD4+ and CD8+ T-cell immunity in women infected during their sexual activity. FUTURE PROSPECTS:
|
Authors | I Bourgault-Villada |
Journal | La Revue de medecine interne
(Rev Med Interne)
Vol. 28
Issue 1
Pg. 22-7
(Jan 2007)
ISSN: 0248-8663 [Print] France |
Vernacular Title | Vaccination anti-Papillomavirus Humains: principes et état d'avancement. |
PMID | 17070619
(Publication Type: English Abstract, Journal Article, Review)
|
Chemical References |
|
Topics |
- Humans
- Papillomavirus Infections
(drug therapy, physiopathology, prevention & control)
- Papillomavirus Vaccines
(therapeutic use)
|